Research Programs Unit of the Faculty of Medicine, University of Helsinki, is a top-quality research environment. Unit’s five research programs comprise groups that integrate clinical, translational and biomedical research. The Program on Translational Cancer Biology applies multiple genetic engineering and stem cell methods, RNAi and chemical biology technologies to investigate tumors in their microenvironment, to identify new therapeutic molecules affecting
genetic driver programs in cancer, and to perform systematic analysis of factors contributing to cellular signaling, reprogramming, migration, and invasion.
Research Programs Unit, Research group of Dr. Pipsa Saharinen invites applications for
in vascular biology for a fixed term of 1 to 4 years.
We are looking for a highly motivated individual with capabilities to work independently and as a part of a dynamic research team. A PhD in cancer / metabolism / angiogenesis / immunology or a related field, as well as excellent communication skills in spoken and written English are required. Experience on imaging, mouse models, molecular biology or protein chemistry are an advantage.
The salary (level 5) will be is based on the salary scheme for Finnish Universities, composed of both task specific and personal performance components.
A trial period of 4 months will be applied.
The application, together with the required attachments, must be submitted through the University of Helsinki electronic recruitment system by clicking on Apply for job. Internal applicants (i.e., current employees of the University of Helsinki), must submit their applications through the SAP HR portal. The application should include a short cover letter describing your areas of expertise, moti-vation for the position, CV and names and contact information of two to three references.
The closing date for applications is July 11th, 2017.
For further information, please contact pipsa.saharinen(at)helsinki.fi, tel. +358-50-4486361.
Recent publications by the Saharinen group:
Saharinen et al., Therapeutic targeting of the angiopoietin–TIE pathway. Nat. Rev. Drug. Disc. 19 May 2017.
Eklund L, Kangas J, Saharinen P. Angiopoietin-Tie signaling in the cardiovascular and lymphatic systems. Clin. Science. 1:87-103, 2017.
Korhonen E, Lampinen A et al. Tie1 controls angiopoietin function in vascular remodeling and in-flammation. J Clin Invest. 126: 3495-3510, 2016.
Hakanpaa et al. Endothelial destabilization by angiopoietin-2 via integrin β1 activation. Nature Commun 6: 5962, 2015.
Apply at latest 11.07.2017
Tuesday, July 11, 2017